OGI Stock Analysis: Buy, Sell, or Hold?
OGI - Organigram Global Inc. Common Shares
$0.95
-0.03 (-2.97%)
▼
5d:
-13.35%
30d:
-19.91%
90d:
-3.6%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When OGI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OGI is down 13.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OGI is down 13.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: OGI is currently trading at $0.95, which is considered oversold relative to its 30-day fair value range of $1.04 to $1.20. From a valuation perspective, the stock is trading at a discount (Forward PE: 39.7) compared to its historical average (57.8). Remarkably, the market is currently pricing in an annual earnings decline of 11.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGI is in a strong uptrend. The price is currently testing key support at $0.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OGI scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.80 (+823.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OGI is in a strong uptrend. The price is currently testing key support at $0.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OGI scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.80 (+823.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.04 -
$1.20
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 823.3% below Wall St target ($8.80)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.04 -
$1.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.95
Resistance Level
$1.13
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
39.71
Wall Street Target
$8.80
(+823.3%)
Revenue Growth (YoY)
49.4%
Profit Margin
28.0%
Valuation Discount vs History
-11.8% cheaper
PE vs Historical
39.7 vs 57.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.8%
(market-implied from PE analysis)
1-Year Target
$0.86
(-10%)
2-Year Target
$0.77
(-19%)
3-Year Target
$0.69
(-27%)
3-Yr Target (if PE normalizes)
(PE: 40→58)
$1.01
(+6%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 39.7, Growth: -94.5%)
$0.69
(+-27%)
Base:
(SPY PE: 20.4, Growth: -94.5%)
$0.36
(-63%)
Bear:
(PE: 17.3, Growth: -94.5%)
$0.30
(-68%)
📈
Valuation based on Current Earnings
Trailing PE: 2.34 | Current EPS (TTM): $0.42
Bull Case
$0.54
(-43%)
Analyst growth -50.0%, PE expands to 2.6
Base Case
$0.49
(-49%)
Market implied -50.0%, PE stable at 2.3
Bear Case
$0.67
(-30%)
Severe decline -20.0%, PE contracts to 2.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 39.7 to 57.8
Stabilization Target:
$1.39
(+45.5%)
PE Expansion Potential:
+45.5%
Share & Embed Analysis
Last updated: October 03, 2026 2:32 AM ET
Data refreshes hourly during market hours. Next update: 3:32 AM
Data refreshes hourly during market hours. Next update: 3:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
